title: [Influence of nocturnal oxygen therapy on quality of life in patients with COPD and isolated sleep-related hypoxemia: a prospective, placebo-controlled cross-over trial].
abstract: BACKGROUND
  In patients with COPD and isolated night time hypoxemia, oxygen administration has not shown any effects on life expectancy and the development of pulmonal arterial hypertension. The aim of the present pilot study was to investigate the influence of nocturnal oxygen therapy on the quality of life in daytime normoxemic COPD patients with nocturnal oxygen desaturations.
  
  
  METHODS
  19 patients with COPD, in a stable phase of the disease without need for oxygen supplementation under rest (PaO2 62.7 +/- 4.9 mmHg) and nocturnal hypoxemia (t90 = 55.5 +/- 33.4 % of registration time, mean SaO2 89.8 +/- 1.9 %, minimal SaO2 81.1 +/- 4.8 %) were randomly assigned to either oxygen or placebo treatment, both generated by identical concentrator devices. Each treatment period lasted 6 weeks, after six weeks a cross-over was performed by a technician. Quality of life was assessed before and at the end of each treatment period by the SF-36, Nottingham Health Profile and Saint George's Respiratory Questionnaire.
  
  
  RESULTS
  Significant differences for the comparison of placebo and verum were only seen for the dimension sleep (NHP), all other dimensions showed no differences between placebo and oxygen. However, both placebo and oxygen improved the majority of the quality of life items significantly.
  
  
  CONCLUSIONS
  The prescription of supplemental oxygen in COPD patients with isolated nocturnal hypoxemia in the present pilot study is not able to improve the quality of life within 6 weeks after initiation of therapy. It cannot, therefore, be generally recommended, but may be indicated in patients with a documented improvement of sleep quality.
authors.affiliation: Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil GmbH, Medizinische Klinik III, Pneumologie, Allergologie, Schlaf- und Beatmungsmedizin, Bochum. maritta.orth@rub.de
authors.forename: M
authors.initials: M
authors.lastname: Orth
authors.forename: J W
authors.initials: JW
authors.lastname: Walther
authors.forename: S
authors.initials: S
authors.lastname: Yalzin
authors.forename: T T
authors.initials: TT
authors.lastname: Bauer
authors.forename: J
authors.initials: J
authors.lastname: de Zeeuw
authors.forename: S
authors.initials: S
authors.lastname: Kotterba
authors.forename: H T
authors.initials: HT
authors.lastname: Baberg
authors.forename: G
authors.initials: G
authors.lastname: Schultze-Werninghaus
authors.forename: K
authors.initials: K
authors.lastname: Rasche
authors.forename: H-W
authors.initials: HW
authors.lastname: Duchna
mesh_terms: D000368:Aged; D018592:Cross-Over Studies; D005260:Female; D005858:Germany / Q000453:epidemiology; D006801:Humans; D000860:Hypoxia / Q000453:epidemiology* / Q000517:prevention & control*; D008297:Male; D010102:Oxygen Inhalation Therapy / Q000706:statistics & numerical data*; D010865:Pilot Projects; D015990:Placebo Effect; D015995:Prevalence; D011446:Prospective Studies; D029424:Pulmonary Disease, Chronic Obstructive / Q000453:epidemiology* / Q000628:therapy*; D011788:Quality of Life; D018570:Risk Assessment / Q000379:methods; D012307:Risk Factors; D016896:Treatment Outcome